-IV). In chemotherapy indications, 31.3% were prescribed for palliative care, with the same percentage for adjuvant therapy and 18% for neoadjuvant and hormonal treatment, respectively. The most frequently prescribed antineoplastic agents were taxanes
Search Results
Andres Garcia, David Medina, Alejandra Palacio, Andrés Vallejo, Luz Adriana Díaz, Juan Darío Franco, Tatiana Taborda, and María José Rojas
Michaela J. Higgins, James M. Rae, David A. Flockhart, Daniel F. Hayes, and Vered Stearns
adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial . Lancet Oncol 2008 ; 9 : 45 – 53 . 48 Coates AS Keshaviah A Thurlimann B . Five years of letrozole compared with tamoxifen as initial adjuvant therapy for
John A. Thompson
-positives. PET/CT may be more useful than conventional CT in the workup of patients who have relatively high pretest probabilities of occult metastatic disease (eg, patients with stage IIIB and IIIC melanoma). Treatment Adjuvant Therapy High
Steven Sorscher
HER2 copy number is less than 4 signals/cell is that….” 2 Based on the pre-2018 ASCO/CAP HER2 classification, whether being used as adjuvant therapy or therapy for metastatic HER2-positive disease, the FDA-approved anti-HER2 therapies offer truly
Wells A. Messersmith
treatment with the best chance of success. Adjuvant Therapy Although 11 agents have been approved by the FDA for CRC, only 3 are used in the adjuvant setting (fluorouracil [5-FU], capecitabine, and oxaliplatin) and only 2 (cetuximab and panitumumab
Michelle Moskal and Neeharika S. Makani
, only 6.3% of high risk stage II and 45.5% of stage III patients received adjuvant therapy. Data showed 100% compliance with initiation of adjuvant 5-FU based chemotherapy within 12 weeks post surgery, which is recommended in high risk stage II and III
Nicole Nardella, Matt Adams, Anjali Mahapatra, Diana Castillo, Sarah Hoffe, Dae Won Kim, Jason Fleming, and Pamela Hodul
adjuvant therapy (n=33). Of those that were resectable, borderline resectable, or locally advanced (n=191), 76% (145/191) had coordinated care secondary to their FC call; 68% of patients saw multiple interdisciplinary providers, with 25% occurring on the
) colorectal cancer who have received prior treatment with a fluoropyrimidine (5-FU or capecitabine) and oxaliplatin or who have experienced a recurrence within 12 months of adjuvant therapy with a regimen that included oxaliplatin. For study purposes, a cycle
Saman S Karimi and Maria Gonzalez
determine the number of positive lymph nodes as an independent prognostic indicator in Stage II colorectal carcinoma, which prompts adjuvant therapy in these patients. This study aimed to assess the average number of lymph nodes in post-neoadjuvant rectal
unresectable) colorectal cancer who have received prior treatment with a fluoropyrimidine (5-FU or capecitabine) and oxaliplatin or who have experienced a recurrence within 12 months of adjuvant therapy with a regimen that included oxaliplatin. For study